图解爱朋医疗中报：第二季度单季净利润同比下降122.95%

Core Viewpoint - The financial performance of Aipeng Medical in the 2025 mid-year report shows significant declines in revenue and net profit, indicating potential challenges for the company moving forward [1][3]. Financial Performance Summary - The main revenue for the first half of 2025 was 159 million yuan, a year-on-year decrease of 11.31% [1][3]. - The net profit attributable to shareholders was -19.38 million yuan, a year-on-year decline of 317.9% [1][3]. - The non-recurring net profit was -20.14 million yuan, down 445.67% year-on-year [1][3]. - In Q2 2025, the single-quarter main revenue was 94.34 million yuan, an increase of 2.87% year-on-year [1][3]. - The single-quarter net profit attributable to shareholders was -1.73 million yuan, a decrease of 122.95% year-on-year [1][3]. - The single-quarter non-recurring net profit was -2.19 million yuan, down 153.38% year-on-year [1][3]. Key Financial Ratios - The debt ratio stood at 18.22% [1]. - Investment income was 1.01 million yuan, while financial expenses were 973,800 yuan [1]. - The gross profit margin was 63.22%, reflecting a year-on-year decrease of 7.28% [6]. - The return on equity was -2.81%, a year-on-year decline of 321.25% [6]. - Earnings per share were -0.15 yuan, down 317.70% year-on-year [6]. - The operating cash flow per share was -0.38 yuan, a significant decrease of 2327.07% year-on-year [6]. Shareholder Information - The top circulating shareholders include Wang Ningyu with 9.02 million shares (10.26%), Beijing Zhanghong Private Fund Management Co., Ltd. with 7.06 million shares (8.03%), and Zhang Zhihui with 3.29 million shares (3.75%) [10].